Longitudinal Multimodal Retinal Imaging in Cognitively Normal Apolipoprotein E4 Carriers and Noncarriers
Translational Vision Science & Technology · 2026
DOI: 10.1167/tvst.15.10.45 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2026. Verfasst von Alex Choi und 8 weiteren Autor:innen. Beteiligte Einrichtung: iMIND Study Group, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Apolipoprotein E4, Multimodal Imaging, Cognition, Retina. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Purpose
To evaluate longitudinal retinal structural and microvascular changes in cognitively normal apolipoprotein E (APOE) ε4 carriers compared with noncarriers.
Methods
Cognitively normal adults with known APOE genotype underwent multimodal retinal imaging at baseline and follow-up visits. Optical coherence tomography (OCT) metrics included macular central subfield thickness (CST), ganglion cell-inner plexiform layer (GC-IPL) thickness, and retinal nerve fiber layer (RNFL) thickness. OCT angiography (OCTA) parameters included vessel and perfusion density across 3-mm and 6-mm circles and rings, peripapillary capillary perfusion density (CPD), and capillary flux index (CFI). Annual rates of change were estimated using linear mixed-effects models adjusted for age and sex. A subgroup analysis was performed in participants with ≥5-year follow-up.
Results
This study analyzed 871 eyes from 439 participants (230 APOE ε4 noncarriers and 209 carriers). Baseline retinal parameters did not differ significantly between groups. Carriers demonstrated nominally slower annual RNFL decline (β = 0.334; P = 0.023) and attenuated peripapillary CPD decline (β = 0.0010; P = 0.014) versus noncarriers; neither survived false discovery rate (FDR) correction (P = 0.18). In the ≥5-year subgroup (n = 58), carriers demonstrated nominally higher peripapillary CPD than noncarriers (P = 0.011; FDR-adjusted P = 0.17), although rates of change did not differ significantly between groups.
Conclusions
Cognitively normal APOE ε4 carriers demonstrated nominally slower peripapillary CPD and RNFL decline over longitudinal follow-up, with carriers maintaining higher CPD at ≥5 years despite comparable baseline imaging. Translational Relevance: Longitudinal peripapillary and RNFL changes may reflect early retinal findings associated with APOE ε4 carrier status prior to cognitive decline, supporting further investigation of longitudinal retinal imaging as a potential noninvasive biomarker in preclinical Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- iMIND Study Group, Duke University School of Medicine, Durham, NC, USA.
- Department of Neurology, Duke University School of Medicine, Durham, NC, USA.
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
- Geriatrics Research Education and Clinical Center, Durham VA Medical Center, Durham, NC, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Choi, A., Haystead, A., D'Cunha, R., Hsu, J., Zhu, M., Johnson, K. G., Whitson, H., Grewal, D. S., & Fekrat, S. (2026). Longitudinal Multimodal Retinal Imaging in Cognitively Normal Apolipoprotein E4 Carriers and Noncarriers. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.15.10.45
Vancouver
Choi A, Haystead A, D'Cunha R, Hsu J, Zhu M, Johnson KG, et al. Longitudinal Multimodal Retinal Imaging in Cognitively Normal Apolipoprotein E4 Carriers and Noncarriers. Translational Vision Science & Technology. 2026. doi:10.1167/tvst.15.10.45
BibTeX
@article{Choi2026,
author = {Choi, Alex and Haystead, Alice and D'Cunha, Rachel and Hsu, John and Zhu, Michael and Johnson, Kim G and Whitson, Heather and Grewal, Dilraj S and Fekrat, Sharon},
title = {Longitudinal Multimodal Retinal Imaging in Cognitively Normal Apolipoprotein E4 Carriers and Noncarriers},
journal = {Translational Vision Science & Technology},
year = {2026},
doi = {10.1167/tvst.15.10.45}
}
EUVIMED